Patients in low and middle-income countries (LMICs) are largely excluded from clinical trials by pharmaceutical companies, limiting their access to life-saving treatments and therapies.
An Access to Medicine Foundation report reveals that pharmaceutical companies tend to conduct trials in countries where they plan to market their products, often neglecting sub-Saharan African countries.